Quoin Shares Corporate Update, Positive Clinical Data and Q3 Financial Results
November 09, 2023 - by Catie Corcoran
Company’s global network now spans 61 countries
In today’s corporate update, Quoin Pharmaceuticals(Nasdaq: QNRX) CEO, Dr. Michael Myers, shared the company’s “significant progress across multiple fronts culminating in the release of additional positive clinical data” for QRX003 in its ongoing Netherton Syndrome clinical trial. Subjects reported reduction in itching, improved skin appearance and satisfaction with QRX003 across multiple endpoints.
Further, Quoin entered into its ninth commercial partnership for QRX003 with FarmaMondo in Singapore, extending its global commercial partnerships to 61 countries. Late-stage discussions with additional countries in Latin America and Southeast Asia continue, with the aim of making QRX003 available to as many patients in as many countries as possible upon approval.
“These partnerships, along with our own planned commercial infrastructure for the U.S. and Europe, will facilitate what will effectively amount to a global launch of the product, once approved, and lay the foundation for similar global launches of pipeline products once they also receive regulatory approval,” Dr. Myers said. “We firmly believe this global commercial network is unprecedented for a company our size and represents a highly differentiated and perhaps somewhat underappreciated advantage for Quoin.
“The potential incremental revenue-generating opportunity that this global commercial partnership network represents, all of which will effectively fall to the bottom line, could ultimately be highly significant for the company and have a materially positive impact on our future profitability.”
Based on patient numbers and its potential price point, Quoin believes the market for QRX003 is “substantially in excess of $500 million in total and could be significantly higher.”
Quoin reported positive benefits across multiple clinical endpoints and no safety concerns in the open-label clinical trial. Dr. Myers noted that Quoin expects “an even more robust clinical data set” that will “potentially lead to a faster and possibly wider initial regulatory approval” for QRX003 based on planned protocol amendments, including increased dosing.
The contract manufacturer for QRX003’s active ingredient has successfully developed and scaled up a new and fully good manufacturing practice (GMP) for the substance; the source of the material is exclusively available to Quoin and the company is also exploring related intellectual property development.
Further, Quoin is “acutely focused” on expanding its product portfolio via acquisition, licensing or other opportunities. The company has narrowed 20 opportunities down to three rare disease products and is actively working on closing at least one of the transactions.
The company reported cash, cash equivalents and marketable securities of approximately $14 million as of Sept. 30, providing a cash runway expected to extend through 4Q 2024. Operating loss for the third quarter was $2.1 million, compared to $2.3 million for Q3 2022, due to lower professional fees and other general costs.
Dr. Myers added, “As we continue to make significant progress on the clinical front ourselves, we and our now nine global marketing partners are more excited than ever by the potential commercial opportunity of what could be the first regulatory approved product for this horrendous disease.”
Share this article:
Disclaimer
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
This communication was produced by Prism MarketView, “PRISM”. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
“PRISM” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PRISM” engage in any activities that would require such registrations. “PRISM” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
This communication may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, market conditions, regulatory developments, and other factors beyond the control of the profiled company. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. PRISM undertakes no obligation to update or revise any such statements.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PRISM” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PRISM”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PRISM” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.
